Cargando…

Merits and culprits of immunotherapies for neurological diseases in times of COVID-19

Immunosuppression and immunomodulation are valuable therapeutic approaches for managing neuroimmunological diseases. In times of the Coronavirus disease 2019 (COVID-19) pandemic, clinicians must deal with the question of whether immunotherapy should currently be initiated or discontinued in neurolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pawlitzki, Marc, Zettl, Uwe K., Ruck, Tobias, Rolfes, Leoni, Hartung, Hans-Peter, Meuth, Sven G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286830/ https://www.ncbi.nlm.nih.gov/pubmed/32535547 http://dx.doi.org/10.1016/j.ebiom.2020.102822

Ejemplares similares

Risiken und Chancen von Immuntherapien in Zeiten der Coronavirus-2019-Pandemie
por: Pawlitzki, Marc, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod—potentials and risks of subsequent highly active agents
por: Korsen, Melanie, et al.
Publicado: (2022)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions
por: Gross, Catharina C., et al.
Publicado: (2020)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
por: Nelke, Christopher, et al.
Publicado: (2021)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?
por: Pawlitzki, Marc, et al.
Publicado: (2019)

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation
por: Rolfes, Leoni, et al.
Publicado: (2021)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

Driving time-based identification of gaps in specialised care coverage: An example of neuroinflammatory diseases in Germany
por: Masanneck, Lars, et al.
Publicado: (2023)

“Neurological manifestations of COVID-19” - guideline of the German society of neurology
por: Berlit, Peter, et al.
Publicado: (2020)

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
por: Rolfes, Leoni, et al.
Publicado: (2021)

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
por: Rolfes, Leoni, et al.
Publicado: (2023)

Classification of neurological diseases using multi-dimensional CSF analysis
por: Gross, Catharina C, et al.
Publicado: (2021)

NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection
por: Pawlitzki, Marc, et al.
Publicado: (2021)

Vaccination and immunotherapies in neuroimmunological diseases
por: Winkelmann, Alexander, et al.
Publicado: (2022)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Thinking outside the box: non-canonical targets in multiple sclerosis
por: Bierhansl, Laura, et al.
Publicado: (2022)

Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab
por: Pfeuffer, Steffen, et al.
Publicado: (2023)

Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits
por: Thöne, Jan, et al.
Publicado: (2013)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study
por: Masanneck, Lars, et al.
Publicado: (2023)

MS-Therapie im Alter - Was gilt es zu bedenken?
por: Pawlitzki, Marc, et al.
Publicado: (2020)

Immunmodulatorische Therapien bei Multipler Sklerose in der Pandemie
por: Pawlitzki, Marc, et al.
Publicado: (2021)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Ocrelizumab initiation in patients with MS: A multicenter observational study
por: Ellwardt, Erik, et al.
Publicado: (2020)

Identifying the culprits in neurological autoimmune diseases
por: Acosta-Ampudia, Yeny, et al.
Publicado: (2019)

The Impact of Dysphagia in Myositis: A Systematic Review and Meta-Analysis
por: Labeit, Bendix, et al.
Publicado: (2020)

Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade
por: Nelke, Christopher, et al.
Publicado: (2023)

Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

Supporting the differential diagnosis of connective tissue diseases with neurological involvement by blood and cerebrospinal fluid flow cytometry
por: Heming, Michael, et al.
Publicado: (2023)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Clinical, Radiological, and Laboratory Features of Spinal Cord Involvement in Primary Sjögren’s Syndrome
por: Butryn, Michaela, et al.
Publicado: (2020)

Consequences of COVID-19 pandemic lockdown on emergency and stroke care in a German tertiary stroke center
por: Jansen, Robin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tn8kuemtpil4a65u0lakrtjp54